A citation-based method for searching scientific literature

J Laskin, S V Liu, K Tolba, C Heining, R F Schlenk, P Cheema, J Cadranel, M R Jones, A Drilon, A Cseh, S Gyorffy, F Solca, M Duruisseaux. Ann Oncol 2020
Times Cited: 17







List of co-cited articles
68 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Detection of NRG1 Gene Fusions in Solid Tumors.
Sushma Jonna, Rebecca A Feldman, Jeffrey Swensen, Zoran Gatalica, Wolfgang M Korn, Hossein Borghaei, Patrick C Ma, Jorge J Nieva, Alexander I Spira, Ari M Vanderwalde,[...]. Clin Cancer Res 2019
70
41

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.
Alexander Drilon, Romel Somwar, Biju P Mangatt, Henrik Edgren, Patrice Desmeules, Anja Ruusulehto, Roger S Smith, Lukas Delasos, Morana Vojnic, Andrew J Plodkowski,[...]. Cancer Discov 2018
83
41

CD74-NRG1 fusions in lung adenocarcinoma.
Lynnette Fernandez-Cuesta, Dennis Plenker, Hirotaka Osada, Ruping Sun, Roopika Menon, Frauke Leenders, Sandra Ortiz-Cuaran, Martin Peifer, Marc Bos, Juliane Daßler,[...]. Cancer Discov 2014
158
35

Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
Dong Hoon Shin, Donghoon Lee, Dong Wan Hong, Seung Hyun Hong, Jung-Ah Hwang, Byung Il Lee, Hye Jin You, Geon Kook Lee, In-Hoo Kim, Yeon-Su Lee,[...]. Oncotarget 2016
40
35

Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Jacques Cadranel, Stephen V Liu, Michaël Duruisseaux, Eva Branden, Yasushi Goto, Benjamin A Weinberg, Christoph Heining, Richard F Schlenk, Parneet Cheema, Martin R Jones,[...]. Oncologist 2021
11
45

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
290
23

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma.
Lucia Anna Muscarella, Domenico Trombetta, Federico Pio Fabrizio, Aldo Scarpa, Vito Michele Fazio, Evaristo Maiello, Antonio Rossi, Paolo Graziano. J Thorac Oncol 2017
14
28

NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?
Domenico Trombetta, Antonio Rossi, Federico P Fabrizio, A Sparaneo, Paolo Graziano, Vito M Fazio, Lucia A Muscarella. Curr Med Chem 2017
13
30

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
23

Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.
Lynnette Fernandez-Cuesta, Roman K Thomas. Clin Cancer Res 2015
41
23

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
366
17

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
128
17

Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression.
Domenico Trombetta, Paolo Graziano, Aldo Scarpa, Angelo Sparaneo, Giulio Rossi, Antonio Rossi, Massimo Di Maio, Davide Antonello, Andrea Mafficini, Federico Pio Fabrizio,[...]. Oncotarget 2018
24
17

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions.
Nathan D Gay, Ying Wang, Carol Beadling, Andrea Warrick, Tanaya Neff, Christopher L Corless, Khaled Tolba. J Thorac Oncol 2017
39
17

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.
Christoph Heining, Peter Horak, Sebastian Uhrig, Paula L Codo, Barbara Klink, Barbara Hutter, Martina Fröhlich, David Bonekamp, Daniela Richter, Katja Steiger,[...]. Cancer Discov 2018
83
17

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Hyo Sup Shim, Mari- Kenudson, Zongli Zheng, Matthew Liebers, Yoon Jin Cha, Quan Hoang Ho, Maristela Onozato, Long Phi Le, Rebecca S Heist, A John Iafrate. J Thorac Oncol 2015
86
17

Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
Takashi Nakaoku, Koji Tsuta, Hitoshi Ichikawa, Kouya Shiraishi, Hiromi Sakamoto, Masato Enari, Koh Furuta, Yoko Shimada, Hideaki Ogiwara, Shun-ichi Watanabe,[...]. Clin Cancer Res 2014
119
17

The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions.
Igor Odintsov, Allan J W Lui, Whitney J Sisso, Eric Gladstone, Zebing Liu, Lukas Delasos, Renate I Kurth, Exequiel M Sisso, Morana Vojnic, Inna Khodos,[...]. Clin Cancer Res 2021
3
100

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.
Martin R Jones, Laura M Williamson, James T Topham, Michael K C Lee, Angela Goytain, Julie Ho, Robert E Denroche, GunHo Jang, Erin Pleasance, Yaoquing Shen,[...]. Clin Cancer Res 2019
45
17

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip,[...]. J Clin Oncol 2018
129
17

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
17

NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.
Michaël Duruisseaux, Anne McLeer-Florin, Martine Antoine, Sanaz Alavizadeh, Virginie Poulot, Roger Lacave, Nathalie Rabbe, Jacques Cadranel, Marie Wislez. Cancer Med 2016
20
17

Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
M R Jones, H Lim, Y Shen, E Pleasance, C Ch'ng, C Reisle, S Leelakumari, C Zhao, S Yip, J Ho,[...]. Ann Oncol 2017
54
17



ERBB receptors and cancer: the complexity of targeted inhibitors.
Nancy E Hynes, Heidi A Lane. Nat Rev Cancer 2005
11

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Howard West, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry J Conter, Hans-Georg Kopp, Davey Daniel, Steven McCune, Tarek Mekhail,[...]. Lancet Oncol 2019
415
11

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
11

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
Ryan J Sullivan, Jeffrey R Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A Sosman, Vicki Keedy, Manish R Patel, Geoffrey I Shapiro, James W Mier, Anthony W Tolcher,[...]. Cancer Discov 2018
159
11

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.
A Lisberg, A Cummings, J W Goldman, K Bornazyan, N Reese, T Wang, P Coluzzi, B Ledezma, M Mendenhall, J Hunt,[...]. J Thorac Oncol 2018
230
11

Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study.
Vivek Subbiah, Radj Gervais, Gregory Riely, Antoine Hollebecque, Jean-Yves Blay, Enriqueta Felip, Martin Schuler, Anthony Gonçalves, Antonio Italiano, Vicki Keedy,[...]. JCO Precis Oncol 2019
19
11

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
11


PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, C A Shu, R Umeton, J Montecalvo, A Ni, R Chen, J Dienstag, C Mrad, I Bergagnini,[...]. Ann Oncol 2018
115
11

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R Kaufman, Andrew Albright, Jonathan D Cheng, S Peter Kang, Veena Shankaran,[...]. J Clin Invest 2017
11

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
11

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.
Anna F Farago, Martin S Taylor, Robert C Doebele, Viola W Zhu, Shivaani Kummar, Alexander I Spira, Theresa A Boyle, Eric B Haura, Maria E Arcila, Ryma Benayed,[...]. JCO Precis Oncol 2018
80
11

Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Dong Hoon Shin, Jeong Yeon Jo, Ji-Youn Han. Mol Cancer Ther 2018
15
13

Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.
Takahiko Murayama, Takashi Nakaoku, Masato Enari, Tatsunori Nishimura, Kana Tominaga, Asuka Nakata, Arinobu Tojo, Sumio Sugano, Takashi Kohno, Noriko Gotoh. Cancer Res 2016
41
11

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Caroline E McCoach, Anh T Le, Katherine Gowan, Kenneth Jones, Laura Schubert, Andrea Doak, Adriana Estrada-Bernal, Kurtis D Davies, Daniel T Merrick, Paul A Bunn,[...]. Clin Cancer Res 2018
94
11

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
11

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
11

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
John D Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R Spigel, Christopher Sweeney, Howard Burris, Ron Bose, Bongin Yoo, Alisha Stein,[...]. J Clin Oncol 2018
200
11

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
742
11

Gene signature driving invasive mucinous adenocarcinoma of the lung.
Minzhe Guo, Koichi Tomoshige, Michael Meister, Thomas Muley, Takuya Fukazawa, Tomoshi Tsuchiya, Rebekah Karns, Arne Warth, Iris M Fink-Baldauf, Takeshi Nagayasu,[...]. EMBO Mol Med 2017
51
11

KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
David H Hwang, Lynette M Sholl, Vanesa Rojas-Rudilla, Dimity L Hall, Priyanka Shivdasani, Elizabeth P Garcia, Laura E MacConaill, Marina Vivero, Jason L Hornick, Frank C Kuo,[...]. J Thorac Oncol 2016
39
11

Spread through air spaces (STAS) in invasive mucinous adenocarcinoma of the lung: Incidence, prognostic impact, and prediction based on clinicoradiologic factors.
Min A Lee, Jun Kang, Ho Yun Lee, Wooil Kim, Insuk Shon, Na Young Hwang, Hong Kwan Kim, Yong Soo Choi, Jhingook Kim, Jae Ill Zo,[...]. Thorac Cancer 2020
5
40

Clinical course of stage IV invasive mucinous adenocarcinoma of the lung.
Yoon Jin Cha, Hye Ryun Kim, Hye-Jeong Lee, Byoung Chul Cho, Hyo Sup Shim. Lung Cancer 2016
21
11

Prognostic impact of mucin spread, tumor cell spread, and invasive size in invasive mucinous adenocarcinoma of the lung.
Tomohito Saito, Koji Tsuta, Osamu Honda, Mitsuaki Ishida, Ryosuke Yamaka, Noriyuki Tanaka, Kaori Ishida, Takahiro Utsumi, Natsumi Maru, Hiroshi Matsui,[...]. Lung Cancer 2020
3
66

Detection of NRG1 Fusions in Solid Tumors: Rare Gold?
Anastasios Dimou, D Ross Camidge. Clin Cancer Res 2019
6
33


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.